Microbiome Modulation for CAR T Cell Toxicity Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR T cell therapies for cancer treatment face challenges in predicting cancer survival and toxicity, with patients experiencing variable responses and toxicities such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, due to factors like CAR T cell persistence, exhaustion, and antigen loss, necessitating improved predictive methods and therapeutic interventions.
Innovation Solution
The use of specific therapeutic bacteria, including Ruminococcus gnavus, Blautia schinkii, and Faecalibacterium prausnitzii, or their spores, which are administered to patients undergoing CAR T cell therapy to modulate the intestinal microbiome, thereby influencing cancer survival and toxicity outcomes by determining bacterial levels and sequence identities, and employing pharmaceutical compositions that include these bacteria to enhance survival and reduce toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR T cell therapy is administered to treat cancer, then cancer survival may be improved, but CAR T cell-associated toxicities such as CRS and ICANS occur
Solution Approach 1:
The patent applies preliminary action by assessing microbiome composition before CAR T cell therapy administration to predict toxicity risk and identify patients who may benefit from microbiome modulation. This predictive assessment is performed in advance to stratify patients and guide personalized treatment strategies, allowing preventive measures to be taken before therapy begins.
Solution Approach 2:
The patent uses the intestinal microbiome as an intermediary factor that mediates between the CAR T cell therapy and the patient's physiological response. By modulating microbiome composition through targeted interventions, the harmful toxicities (CRS and ICANS) can be reduced while preserving the therapeutic anti-tumor effects, thus resolving the contradiction between efficacy and safety.
2Reliability
If CAR T cell therapy is administered, then anti-tumor function is achieved, but precision in predicting which patients will develop toxicities and to what degree cannot be achieved with current methods
Solution Approach 1:
The patent implements feedback by using baseline microbiome composition data to predict individual patient responses to CAR T cell therapy. The microbiome profile serves as a feedback mechanism that provides precise information about a patient's likelihood of developing toxicities, enabling personalized risk stratification and guiding clinical decision-making with high precision.
Solution Approach 2:
The patent applies parameter changes by focusing on specific microbiome parameters (bacterial composition, diversity indices) as predictive markers. By analyzing changes in these microbiome parameters before therapy, the system achieves precise prediction of toxicity outcomes, moving beyond non-specific risk factors to measurable, actionable parameters that individualize patient prognosis.
3Ease of operation
If known risk factors such as tumor burden and CAR T cell dose are used for prediction, then some predictive capability is achieved, but these factors fail to predict with precision which patients will develop toxicities
Solution Approach 1:
The patent introduces the microbiome as an intermediary predictive factor that bridges the gap between standard risk factors and actual toxicity outcomes. While tumor burden and dose provide coarse predictions, the microbiome composition acts as a mediating variable that refines these predictions to the individual patient level, achieving precise toxicity prediction without complicating the clinical workflow.
Data Source
AI summary
The present disclosure relates to compositions and methods for predicting cancer survival or toxicity in a subject receiving a chimeric antigen receptor (CAR) T cell therapy. The present disclosure further discloses compositions, e.g., pharmaceutical compositions, and methods for treating said subject.